Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Chief Financial Officer
Effective as of August 13, 2018, Maximilian Scheder-Bieschin retired as the Chief Financial Officer and Secretary of Ekso Bionics Holdings, Inc. (the “Company”). Mr. Scheder-Bieschin will remain an employee of the Company through the end of August. After that, Mr. Scheder-Bieschin will serve as a consultant to the Company until December 31, 2018, to the terms of a Transition Services Agreement dated May 7, 2018 (the “Transition Agreement”) by and between the Company and Mr. Scheder-Bieschin, and will continue to assist the Company’s new Chief Financial Officer, Mr. Jack Glenn, in the transition process.
Appointment of New Chief Financial Officer
On August 1, 2018, John (Jack) Glenn accepted an offer of employment from the Company to serve as the new Chief Financial Officer of the Company (the “Offer Letter”), effective August 13, 2018 (the “Effective Date”). Mr. Glenn will also serve as the Company’s new Secretary.
Mr. Glenn brings 25 years of financial leadership experience in public and private companies in the life sciences industry. From March 2018 until now, Mr. Glenn has been working as a consultant to biotechnology and medical device companies. In such role, Mr. Glenn has been advising senior management of such companies in respect of financial, accounting and operational matters, including fundraising, development of internal controls and processes and budgeting. From 2016 to 2017, Mr. Glenn served as the Chief Financial Officer of Sonendo Inc., a privately-held, venture-backed company developing technology for dental root canal therapy. In that role, Mr. Glenn worked on strategic initiatives, including corporate development and financing. From 2015 to 2016, Mr. Glenn served as the Chief Financial Officer of Armetheon, Inc., a privately-held biopharmaceutical company. From January 2008 to January 2014, Mr. Glenn served as the Chief Financial Officer of Solta Medical, Inc., where he assisted in the strategic acquisition by Valeant Pharmaceuticals International, Inc. of this then-Nasdaq-listed company that designed, developed, manufactured and marketed energy-based medical device systems for aesthetic applications
to his Offer Letter, Mr. Glenn’s annual base salary will be $275,000 and is subject to increase as determined by the Board. Mr. Glenn will also receive a signing bonus of $25,000. In addition, Mr. Glenn will be eligible to receive an annual bonus with a target bonus amount of 40% of his annual base salary, all or a portion of which may, at the discretion of the Board, be based on the achievement of certain operational, financial or other milestones established by the Board. The Company has agreed to grant Mr. Glenn an option to purchase 400,000 shares of its common stock at the fair market value of the Company’s common stock, as determined by the Compensation Committee of the Board on the date the Compensation Committee approves the grant. The option will become exercisable over a 4-year period, with 1/4th of the shares becoming exercisable on the first anniversary of the date of Mr. Glenn’s employment with the Company and with 1/48th of the shares becoming exercisable at the end of each month thereafter. In addition, Mr. Glenn will be eligible to receive an additional option grant in 2019 which will have a grant date fair value that will be no less than the fair value of an option to purchase 100,000 shares granted on the Effective Date.
Mr. Glenn will be entitled to receive perquisites and other fringe benefits that may be provided to, and will be eligible to participate inany other bonus or incentive program established by us, for the Company’s executives. Mr. Glenn and his dependents will also be entitled to participate in any of the Company’s employee benefit plans subject to the same terms and conditions applicable to other employees.Mr. Glenn will be entitled to be reimbursed for all reasonable travel, entertainment and other expenses incurred by him for the purpose of conducting the Company’s business, in accordance with Company policy.
In the event that Mr. Glenn is terminated by the Company without cause prior to the first anniversary of the Effective Date, Mr. Glenn will receive continued payment of his base salary for 6 months as severance. If Mr. Glenn is terminated by the Company without cause on or after the first anniversary of the Effective Date, Mr. Glenn will receive continued payment of his base salary for 9 months as severance. The Company will also pay Mr. Glenn’s COBRA premiums equivalent to the employer contribution cost of his continued participation in the Company’s group health, dental, and vision insurance plan for the duration of the applicable severance period based on the service year in which he was terminated.
If there is a change of control during Mr. Glenn’s employment, and if he is terminated without cause within one-year following that change of control, the Company will provide Mr. Glenn with (a) continued payment of base salary for 9 months; (b) the target bonus amount prorated for the 9 month severance period; (c) continuation of or reimbursement for coverage under the Company’s medical, dental, and vision plans; and (d) acceleration of all unvested equity.
Effective as of August 13, 2013, the Company and Mr. Glenn entered into a definitive employment agreement on substantively the same terms as those provided in his Offer Letter.
No “family relationship,” as that term is defined in Item 401(d) of Regulation S-K, exists among Mr. Glenn, on the one hand, and any of the Company’s directors or executive officers, on the other hand.
On August 13, 2018, the Company issued a press release announcing the appointment of Mr. Glenn as the Company’s new Chief Financial Officer. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01. Financial Statements and Exhibits.
EKSO BIONICS HOLDINGS, INC. ExhibitEX-10.1 2 tv500802_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 1414 Harbour Way S Suite 1201 Richmond,…To view the full exhibit click here
